Today's announcement by Cell Press represents an important change that will make a large part of the Cell Press journal archive freely accessible to the worldwide biomedical research community. Cell Press President and CEO Lynne Herndon commented, "Our main goal is the dissemination of information and the active support of scientific exchange. In recognition of the opportunities afforded by electronic publishing, Cell Press is taking this decision in order to better meet the needs of our unique author and reader communities. This opportunity also allows us to incorporate the notion of an open archive without adopting the pay-for-publication model that we believe is untested from both an editorial and financial perspective."
Arie Jongejan, CEO Science & Technology, Elsevier added: "Cell Press publishes a suite of journals with a unique profile in biomedicine. Its readers expect science with immediate impact and its authors expect specialized care and extra speed. We support Cell Press' unique role in the life sciences and within Elsevier."
Cell Press is committed to improving scientific communication through the publication of exciting biology research and reviews. Our mission is to continue to publish and develop journals that deliver the highest possible intellectual rigor, promote community trust, and are widely disseminated. To that end, we are pleased to be able to add our new policy to existing Elsevier initiatives:
- Participation in the HINARI project of the WHO, which distributes journals for free to developing countries (http://www.healthinternetwork.org/index.php);
- A liberal copyright policy that gives authors broad rights;
- Free advance online publication of selected papers;
- Investment in making the entire back-issue collection available online;
- Online submission and review for the convenience of authors and reviewers;
- Support of the research community via meeting sponsorships
About Cell Press
Cell Press, an imprint of Elsevier, publishes prestigious highly cited biomedical research journals. Each Cell Press journal is a leading source for research in its field. The journals include Cell (www.cell.com), Neuron (www.neuron.org), Immunity (www.immunity.com), Molecular Cell (www.molecule.org), Developmental Cell (www.developmentalcell.com), Cancer Cell (www.cancercell.org), Current Biology (www.current-biology.com), Structure (www.structure.org), Chemistry & Biology (www.chembiol.com), and the new journal Cell Metabolism (www.cellmetabolism.org), which will launch in January 2005. The Cell Metabolism recent archive will become freely accessible beginning in January 2006.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical, and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 6,800 employees in 86 offices worldwide publish more than 1,800 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.news.scopus.com/), bibliographic databases, online reference works, and subject-specific portals.
Elsevier (http://www.elsevier.com/) is a global company headquartered in Amsterdam, The Netherlands and has offices worldwide. The company is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education, and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).